RESUMO
PURPOSE: In coronavirus disease 2019 (COVID-19) patients, clinical manifestations as well as chest CT lesions are variable. Lung scintigraphy allows to assess and compare the regional distribution of ventilation and perfusion throughout the lungs. Our main objective was to describe ventilation and perfusion injury by type of chest CT lesions of COVID-19 infection using V/Q SPECT/CT imaging. PATIENTS AND METHODS: We explored a national registry including V/Q SPECT/CT performed during a proven acute SARS-CoV-2 infection. Chest CT findings of COVID-19 disease were classified in 3 elementary lesions: ground-glass opacities, crazy-paving (CP), and consolidation. For each type of chest CT lesions, a semiquantitative evaluation of ventilation and perfusion was visually performed using a 5-point scale score (0 = normal to 4 = absent function). RESULTS: V/Q SPECT/CT was performed in 145 patients recruited in 9 nuclear medicine departments. Parenchymal lesions were visible in 126 patients (86.9%). Ground-glass opacities were visible in 33 patients (22.8%) and were responsible for minimal perfusion impairment (perfusion score [mean ± SD], 0.9 ± 0.6) and moderate ventilation impairment (ventilation score, 1.7 ± 1); CP was visible in 43 patients (29.7%) and caused moderate perfusion impairment (2.1 ± 1.1) and moderate-to-severe ventilation impairment (2.5 ± 1.1); consolidation was visible in 89 patients (61.4%) and was associated with moderate perfusion impairment (2.1 ± 1) and severe ventilation impairment (3.0 ± 0.9). CONCLUSIONS: In COVID-19 patients assessed with V/Q SPECT/CT, a large proportion demonstrated parenchymal lung lesions on CT, responsible for ventilation and perfusion injury. COVID-19-related pulmonary lesions were, in order of frequency and functional impairment, consolidations, CP, and ground-glass opacity, with typically a reverse mismatched or matched pattern.
Assuntos
COVID-19 , COVID-19/diagnóstico por imagem , Humanos , Pulmão/diagnóstico por imagem , Sistema de Registros , SARS-CoV-2 , Cintilografia de Ventilação/PerfusãoRESUMO
In patients with novel coronavirus disease 2019 (COVID-19) referred for lung scintigraphy because of suspected pulmonary embolism (PE), there has been an ongoing debate within the nuclear medicine community as to whether and when the ventilation imaging should be performed. Indeed, whereas PE diagnosis typically relies on the recognition of ventilation-perfusion (V/P) mismatched defects, the ventilation procedure potentially increases the risk of contamination to health-care workers. The primary aim of this study was to assess the role of ventilation imaging when lung scintigraphy is performed because of suspected PE in COVID-19 patients. The secondary aim was to describe practices and imaging findings in this specific population. Methods: A national registry was created in collaboration with the French Society of Nuclear Medicine to collect lung scans performed on COVID-19 patients for suspected PE. The practices of departments were assessed regarding imaging protocols and aerosol precautions. A retrospective review of V/P SPECT/CT scans was then conducted. Two physicians masked to clinical information reviewed each case by sequentially viewing perfusion SPECT, perfusion SPECT/CT, and V/P SPECT/CT images. The scans were classified into 1 of the 4 following categories: patients for whom PE could reasonably be excluded on the basis of perfusion SPECT only, perfusion SPECT/CT, or V/P SPECT/CT and patients with mismatched defects suggestive of PE according to the European Association of Nuclear Medicine criteria. Results: Data from 12 French nuclear medicine departments were collected. Lung scans were performed between March 2020 and April 2021. Personal protective equipment and dedicated cleaning procedures were used in all departments. Of the 145 V/Q SPECT/CT scans included in the central review, PE could be excluded using only perfusion SPECT, perfusion SPECT/CT, or V/P SPECT/CT in 27 (19%), 55 (38%), and 45 (31%) patients, respectively. V/P SPECT/CT was positive for PE in 18 (12%) patients, including 12 (67%) with a low burden of PE (≤10%). Conclusion: In this population of COVID-19 patients assessed with lung scintigraphy, PE could confidently be excluded without the ventilation imaging in only 57% of patients. Ventilation imaging was required to confidently rule out PE in 31% of patients. Overall, the prevalence of PE was low (12%).
Assuntos
COVID-19 , Embolia Pulmonar , COVID-19/diagnóstico por imagem , Humanos , Pulmão/diagnóstico por imagem , Embolia Pulmonar/diagnóstico por imagem , Tomografia Computadorizada de Emissão de Fóton Único/métodos , Relação Ventilação-PerfusãoRESUMO
PURPOSE: In order to avoid the microbiological risks linked to human serum albumin macroaggregates (MAA) used for lung perfusion scintigraphy, we developed a new starch-based Tc-99m potential radiopharmaceutical. METHODS: Microparticles were prepared from oxidised starch coupled to natural polyamine for Tc-99m complexation. Suspensions were formulated as ready-to-use kits for easy one-step labelling procedures. RESULTS: Particle-size analysis, electron microscopy, and confocal microscopy were performed for microparticle characterisation, and gave a typical size distribution ranging from 7 to 63 microm, with a homogenous population of spherical or oval-shaped microparticles. Radiochemical purity exceeded 95%, and was stable for at least 8 h. When challenged with histidine and human plasma, labelling was also stable. Dynamic scintigraphic acquisitions and biodistribution studies conducted on healthy Wistar rats showed a tracer accumulation with more than 80% of the ID in the lungs after 15 min. CONCLUSIONS: With clinically significant characteristics such as a lung half-life of 3 h, a lung-to-vascular ratio of 900, and a lung-to-liver ratio of 90, starch-based microparticles exhibit all the qualities for an effective new lung perfusion agent.
Assuntos
Pulmão/diagnóstico por imagem , Pulmão/metabolismo , Reconhecimento Automatizado de Padrão/métodos , Compostos Radiofarmacêuticos/farmacocinética , Amido/química , Tecnécio/farmacocinética , Animais , Portadores de Fármacos/química , Marcação por Isótopo/métodos , Masculino , Tamanho da Partícula , Imagem de Perfusão/métodos , Compostos Radiofarmacêuticos/síntese química , Ratos , Ratos Wistar , Reprodutibilidade dos Testes , Sensibilidade e Especificidade , Tecnécio/químicaRESUMO
Rhenium sulfide colloidal nanoparticles with average size 5.5 nm were synthesized. Characterizations by ultraviolet-visible spectrophotometry, transmission electron microscopy, energy dispersive X-ray spectrum, and X-ray powder diffraction verified the formation of ReS(2) rhenium sulfide colloidal nanoparticles. The colloidal nanoparticles had good stability and they could be stored stably for 1 week in water. Surface modification by organic molecules improved the stability of the rhenium sulfide nanoparticles. The small-sized rhenium sulfide nanoparticles may be useful for their promising applications in tracing diagnosis and therapy of tumor diseases.
Assuntos
Coloides/química , Nanopartículas Metálicas/química , Rênio/química , Enxofre/química , Microscopia Eletrônica de Transmissão , Espectrofotometria Ultravioleta , Difração de Raios XRESUMO
By focusing on rat glioma, we elucidated whether new lipid nanocapsules (LNC) were able to improve anticancer hydrophobic drug bioavailability while also overcoming multidrug resistance. Blank LNCs and LNCs loaded with the antineoplastic agent paclitaxel were formulated by an emulsion inversion phase process. Expression of efflux pumps by rat glioma cells was assessed by reverse transcription-PCR, Western blot, and immunohistochemistry, and their activity was followed using the tracer (99)Tc(m)-methoxyisobutylisonitrile. Modalities of LNC action were addressed by using confocal microscopy detection of fluorescently labeled LNCs, fluorescence-activated cell sorting, high-performance liquid chromatography measurement of paclitaxel release, and analysis of tumor cell growth. This revealed an interaction between LNCs and efflux pumps that resulted in an inhibition of multidrug resistance in glioma cells, both in culture and in cell implants in animals. LNCs were able to target the intracellular compartment of glioma cells, a mechanism that was abrogated by using intracellular cholesterol inhibitors but not by clathrin-coated pit or caveolae uptake inhibitors. This result can be correlated to the LNC inhibitory effects on efflux pump activity that is itself known to be stimulated by intracellular cholesterol. In parallel, we showed that paclitaxel-loaded LNCs were active reservoirs from which paclitaxel could be released. Finally, we established that paclitaxel-loaded LNCs were more efficient than the commercially available paclitaxel formulation (Taxol) for clinical use, thus reducing tumor expansion in vitro and in vivo. Considering the physiologically compatible nature of LNC excipients, these data may represent an important step towards the development of new clinical therapeutic strategies against cancers.
Assuntos
Antineoplásicos/administração & dosagem , Portadores de Fármacos/química , Resistencia a Medicamentos Antineoplásicos/efeitos dos fármacos , Glioma/tratamento farmacológico , Nanoestruturas/química , Subfamília B de Transportador de Cassetes de Ligação de ATP/análise , Subfamília B de Transportador de Cassetes de Ligação de ATP/genética , Subfamília B de Transportador de Cassetes de Ligação de ATP/metabolismo , Membro 1 da Subfamília B de Cassetes de Ligação de ATP/análise , Membro 1 da Subfamília B de Cassetes de Ligação de ATP/genética , Membro 1 da Subfamília B de Cassetes de Ligação de ATP/metabolismo , Animais , Cápsulas/administração & dosagem , Cápsulas/metabolismo , Portadores de Fármacos/metabolismo , Resistência a Múltiplos Medicamentos/efeitos dos fármacos , Endocitose , Glioma/metabolismo , Masculino , Nitrilas/análise , Paclitaxel/administração & dosagem , RNA Mensageiro/análise , RNA Mensageiro/metabolismo , Ratos , Ratos Endogâmicos F344 , Membro 4 da Subfamília B de Transportadores de Cassetes de Ligação de ATPRESUMO
BACKGROUND AND AIM: It has been shown that the use of a cocktail of isotopes of different ranges of action leads to an increase in the effectiveness of metabolic radiotherapy. The purpose of the present study was to compare with a control group the effectiveness of three different treatments in rats bearing hepatocellular carcinoma (HCC), using (1) a mixture of lipiodol labelled with both I and Re, (2) lipiodol labelled with I alone and (3) lipiodol labelled with Re alone. MATERIAL AND METHODS: Four groups were made up, each containing 14 rats with the N1-S1 tumour cell line. Group 1 received a mixture composed of 22 MBq of Re-SSS lipiodol and 7 MBq I-lipiodol. Group 2 received 14 MBq I-lipiodol. Group 3 received 44 MBq of Re-SSS lipiodol and group 4 acted as the control. The survival of the various groups was compared by a non-parametric test of log-rank, after a follow-up of 60, 180 and 273 days. RESULTS: Compared with the controls, the rats treated with a mixture of Re-SSS lipiodol and I-lipiodol show an increase in survival, but only from day 60 onwards (P=0.05 at day 60 and 0.13 at days 180 and 273). For the rats treated with I-lipiodol, there was a highly significant increase in survival compared with the controls at day 60, day 180 and day 273 (P=0.03, 0.04 and 0.04, respectively). There is no significant increase in survival for the rats treated with Re-SSS lipiodol, irrespective of the follow-up duration (P=0.53 at day 60, 0.48 at day 180, and 0.59 at day 273). CONCLUSIONS: In this study, I-lipiodol is the most effective treatment in HCC-bearing rats, because this is the only method that leads to a prolonged improvement of survival. These results cannot necessarily be extrapolated to humans because of the relatively small size and unifocal nature of the lesions in this study. It appears necessary to carry out a study in humans with larger tumours in order to compare these three treatments, particularly with a view to replacing I-labelled lipiodol by Re-labelled lipiodol. However, this study clearly demonstrated that, for small tumours, as in an adjuvant setting for example, I-labelled lipiodol should be a better option than Re-labelled lipiodol.
Assuntos
Carcinoma Hepatocelular/radioterapia , Radioisótopos do Iodo/administração & dosagem , Óleo Iodado/administração & dosagem , Neoplasias Hepáticas/radioterapia , Compostos Organometálicos/administração & dosagem , Taxa de Sobrevida , Animais , Combinação de Medicamentos , Feminino , Prognóstico , Compostos Radiofarmacêuticos/administração & dosagem , Ratos , Ratos Sprague-Dawley , Análise de Sobrevida , Resultado do TratamentoRESUMO
BACKGROUND: Although intra-arterial radiation therapy with 131I-lipiodol is a useful therapeutic approach to the treatment of hepatocellular carcinoma, various disadvantages limit its use. AIM: To describe the development of a method for the labelling of lipiodol with 188Re-SSS (188Re (S2CPh)(S3CPh)2 complex) and to investigate its biodistribution after injection into the hepatic artery of rats with hepatoma. METHODS: 188Re-SSS lipiodol was obtained after dissolving a chelating agent, previously labelled with 188Re, in cold lipiodol. The radiochemical purity (RCP) of labelling was checked immediately. The 188Re-SSS lipiodol was injected into the hepatic artery of nine rats with a Novikoff hepatoma. They were sacrificed 1, 24 and 48 h after injection, and used for ex vivo counting. RESULTS: Labelling of 188Re-SSS lipiodol was achieved with a yield of 97.3+/-2.1%. The immediate RCP was 94.1+/-1.7%. Ex vivo counting confirmed a predominantly hepatic uptake, with a good tumoral retention of 188Re-SSS lipiodol, a weak pulmonary uptake and a very faint digestive uptake. The 'tumour/non-tumoral liver' ratio was high at 1, 24 and 48 h after injection (2.9+/-1.5, 4.1+/-/4.1 and 4.1+/-0.7, respectively). CONCLUSIONS: Using the method described here, 188Re-SSS lipiodol can be obtained with a very high yield and a satisfactory RCP. The biodistribution in rats with hepatoma indicates a good tumoral retention of 188Re-SSS lipiodol associated with a predominant hepatic uptake, a weak pulmonary uptake and a very faint digestive uptake. This product should be considered for intra-arterial radiation therapy in human hepatoma.
Assuntos
Carcinoma Hepatocelular/metabolismo , Óleo Iodado/administração & dosagem , Óleo Iodado/farmacocinética , Marcação por Isótopo/métodos , Neoplasias Hepáticas/metabolismo , Compostos Organometálicos/administração & dosagem , Compostos Organometálicos/farmacocinética , Animais , Combinação de Medicamentos , Avaliação Pré-Clínica de Medicamentos , Feminino , Injeções Intra-Arteriais , Taxa de Depuração Metabólica , Especificidade de Órgãos , Compostos Radiofarmacêuticos/administração & dosagem , Compostos Radiofarmacêuticos/síntese química , Compostos Radiofarmacêuticos/farmacocinética , Ratos , Ratos Sprague-Dawley , Distribuição Tecidual , Contagem Corporal TotalRESUMO
PURPOSE: This study focuses on a promising carrier system for imaging and therapeutic purposes using lipid nanocapsules. To assess their potential for clinical use, we labelled nanocapsules with (99m)Tc and (188)Re and analysed some kinetic biodistribution parameters after intravenous injection in rats. METHODS: Lipophilic complexes [(99m)Tc/(188)Re(S(3)CPh)(2)(S(2)CPh)] ((99m)Tc/(188)Re-SSS) were encapsulated within the nanoparticles during their manufacture with quantitative yield and satisfactory radiochemical purity. Rats were injected intravenously with 3.7 MBq (99m)Tc/(188)Re-labelled nanocapsules and sacrificed at 5, 15 and 30 min and 1, 2, 4, 8, 12, 16, 20 and 24 h. RESULTS: Dynamic scintigraphic acquisitions showed predominant hepatic uptake, and ex vivo counting indicated a long circulation time of labelled nanocapsules, with a half-life of 21+/-1 min for (99m)Tc and 22+/-2 min for (188)Re. Very weak urinary elimination was observed, indicating good stability of (99m)Tc and (188)Re labelling. CONCLUSION: (99m)Tc/(188)Re-SSS nanocapsules can be obtained with high yield and satisfactory radiochemical purity. The biodistributions of (99m)Tc/(188)Re-labelled nanocapsules are close to those of classical PEG-coated particles and show good stability of (188)Re/(99m)Tc-SSS labelling.
Assuntos
Portadores de Fármacos/química , Lipídeos/química , Nanotubos/química , Radioisótopos/farmacocinética , Rênio/farmacocinética , Tecnécio/farmacocinética , Animais , Marcação por Isótopo/métodos , Masculino , Taxa de Depuração Metabólica , Especificidade de Órgãos , Radioisótopos/química , Radioisótopos/uso terapêutico , Compostos Radiofarmacêuticos/síntese química , Compostos Radiofarmacêuticos/farmacocinética , Compostos Radiofarmacêuticos/uso terapêutico , Ratos , Ratos Wistar , Rênio/química , Rênio/uso terapêutico , Tecnécio/química , Tecnécio/uso terapêutico , Distribuição TecidualRESUMO
PURPOSE: Previous studies have shown that the use of Lipiodol UltraFluid (LUF) emulsified with water leads to an increase in the tumoral uptake of iodine I 131-labeled LUF and reduced pulmonary uptake. Although emulsions containing LUF are currently used for chemoembolization of hepatocellular carcinomas (HCCs), this approach is impossible with intraarterial radiation therapy (RT) because of the problems of radiation protection linked to instability of the emulsions. The aims of this study were to develop stabilized emulsions of radiolabeled LUF of different particle sizes and viscosities and to study its biodistribution in rats with HCC. MATERIALS AND METHODS: An emulsifier made of polyethylene glycol and hydrogenated castor oil was used to stabilize emulsions containing water and technetium Tc 99m-labeled Super Six Sulfur LUF. The various emulsions were injected in the hepatic arteries of rats with HCC. Twenty-four hours after injection, the rats were killed and the liver, tumor, and lungs were removed to perform ex-vivo gamma-counting to quantify tumoral, hepatic, and pulmonary uptake. RESULTS: Emulsions of oil in water and water in oil of different viscosities (0.68-1.06 Pa.S) and particle size distributions (21-45 mum) were prepared and kept stable for more than 24 hours. Whatever the type of emulsion, the observed effect on tumoral uptake was the opposite of that expected. Indeed, a decrease in tumoral activity was observed (P < .05 in three of five cases) and a tendency toward increased pulmonary activity was observed (P < .05 in two of five cases) rather than any significant decrease. CONCLUSIONS: This study made it possible to develop emulsions of radiolabeled iodized oil that remain stable for more than 24 hours. However, studies of biodistribution in rats with HCC failed to demonstrate any improvement in tumoral targeting, but rather showed a decrease in tumoral uptake that renders this approach impractical for intraarterial radiolabeled iodized oil RT as well as for intraarterial iodized oil chemoembolization. These results may possibly be explained by the use of an emulsifier containing lipophilic and hydrophilic components that modify the properties of LUF.
Assuntos
Carcinoma Hepatocelular/metabolismo , Meios de Contraste/metabolismo , Óleo Iodado/metabolismo , Neoplasias Hepáticas Experimentais/metabolismo , Animais , Emulsões , Feminino , Fígado/metabolismo , Pulmão/metabolismo , Tamanho da Partícula , Ratos , Ratos Sprague-Dawley , Distribuição Tecidual , ViscosidadeRESUMO
Iron oxide nanoparticles are used in vivo as contrast agents in magnetic resonance imaging. Their widely used polymer coatings are directly involved in their biocompatibility and avoid magnetic aggregation. As these polymer brushes also limit their tissular diffusion due to important hydrodynamic sizes, this work looks to obtain particles coated with thin layers of organic biocompatible molecules. Coating molecules were chosen depending on their fixation site on iron cores; carboxylates, sulfonates, phosphates, and phosphonates, and, among them, analogs of the phosphorylcholine. Two coating procedures (dialysis and exchange resins purification) were evaluated for hydrodynamic size, total iron concentration, electrophoretic mobility, and colloidal stability. Furthermore, a complementary test on stainless steel plates evaluated the contamination by competition of phosphonates as a rough estimation of the biocompatibility of the particles. Coating with bisphosphonates, the more interesting fixation moiety, leads to small (less than 15 nm) and stable objects in a wide range of pH including the neutrality. From stability data, the coating density was evaluated at around 1.6 molecules per nm(2). Including a quaternary ammonium salt to the coating molecule lowers their electrophoretic mobility. Moreover, this type of coating protects steel plates against contamination without significant desorption. All these properties allow further developments of these nanoparticles for biomedical applications. Copyright 2001 Academic Press.
RESUMO
The aim of this study was to detect salvageable peri-infarction myocardium by MRI in rats after infarction, using with a double contrast agent (CA) protocol at 7 Tesla. Intravascular superparamagnetic iron oxide (SPIO) nanoparticles and an extracellular paramagnetic CA (Gd-DOTA) were used to characterize the peri-infarction zone, which may recover function after reperfusion occurs. Infarcted areas measured from T1-weighted (T1-w) images post Gd-DOTA administration were overestimated compared to histological TTC staining (52% +/- 3% of LV surface area vs. 40% +/- 3%, P=0.03) or to T2-w images post SPIO administration (41% +/- 4%, P=0.04), whereas areas measured from T2-w images post SPIO administration were not significantly different from those measured histologically (P=0.7). Viable and nonviable myocardium portions of ischemically injured myocardium were enhanced after diffusive Gd-DOTA injection. The subsequent injection of vascular SPIO nanoparticles enables the discrimination of viable peri-infarction regions by specifically altering the signal of the still-vascularized myocardium.
Assuntos
Meios de Contraste , Compostos Heterocíclicos , Ferro , Imageamento por Ressonância Magnética/métodos , Infarto do Miocárdio/patologia , Compostos Organometálicos , Óxidos , Pericárdio/patologia , Análise de Variância , Animais , Processamento de Imagem Assistida por Computador , Nanotecnologia , Tamanho da Partícula , RatosRESUMO
OBJECTIVE: to assess the changes in local brain PO2, PCO2, pH (PO2br, PCO2br, pHbr) measured by a intraparenchymal probe (Neurotrend, Codeman) and compare them to simultaneous recording of cerebral PvO2 and blood flow (CBF). METHODS: Arterial, venous longitudinal sinus blood samples and CBF were analyzed in 8 adult anesthetized, ventilated goats. Three step increase of intracranial pressure (ICP) (16, 22, 29 mm Hg) were performed by inflation of an epidural balloon. At each ICP level, similar changes in MAP and in PaCO2 were performed. RESULTS: At constant PaCO2 and MAP, balloon inflation induced a fast response: a decrease of PO2br, PCO2br and pHbr (starting 14 +/- 12 sec, 45 +/- 23 sec and 55 +/- 19 sec after the peak ICP, respectively). Since the second inflation level, PO2br decreased (p < 0.05) despite an ICP returning at 22 mm Hg and a cerebral perfusion pressure (CPP) larger than 90 mmHg. During changes in PaCO2, PO2br paralleled CBF and PvO2 before the second balloon inflation but diverged at higher ICP. In the same time pH-pHbr gradient rose. Hypotension did not induce sizeable changes. CONCLUSIONS: The direct metabolic monitoring of cerebral tissue locally compressed show fast response. At steady state, it shows alterations which are not detected by the measurement of the oxygen saturation in the longitudinal sinus or that of CBF. It confirms that the threshold for ICP which may require therapy in presence of focal brain compression is around 20 mm Hg even in the presence of a CPP > 90 mm Hg.